Brain: normal variations and benign findings in fluorodeoxyglucose-PET/computed tomography imaging.
Brain 18F-fluorodeoxyglucose (18F-FDG) PET allows the in vivo study of cerebral glucose metabolism, reflecting neuronal and synaptic activity. 18F-FDG-PET has been extensively used to detect metabolic alterations in several neurologic diseases compared with normal aging. However, healthy subjects have variants of 18F-FDG distribution, especially as associated with aging. This article focuses on 18F-FDG-PET findings in so-called normal brain aging, and in particular on metabolic differences occurring with aging and as a function of people’s gender. The effect of different substances, medications, and therapy procedures are discussed, as well as common artifacts.
Valentina
V
Berti
Lisa
L
Mosconi
Alberto
A
Pupi
D000375:Aging / Q000378:metabolism; D016477:Artifacts; D001786:Blood Glucose / Q000378:metabolism; D001921:Brain / Q000000981:diagnostic imaging* / Q000378:metabolism; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D006801:Humans; D008297:Male; D064847:Multimodal Imaging / Q000379:methods* / Q000592:standards; D049268:Positron-Emission Tomography / Q000379:methods* / Q000592:standards; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D012727:Sex Characteristics; D014057:Tomography, X-Ray Computed / Q000379:methods* / Q000592:standards
D001786:Blood Glucose; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18